BioNTech SE
(NASDAQ : BNTX)

( )
BNTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 2.41%163.890.0%$1379.69m
AMGNAmgen, Inc. 0.45%250.751.3%$694.75m
NVAXNovavax, Inc. 2.90%207.1880.0%$587.68m
SNSSSunesis Pharmaceuticals, Inc. 0.00%7.880.7%$550.84m
ILMNIllumina, Inc. 0.00%398.073.5%$515.02m
GILDGilead Sciences, Inc. 0.46%65.601.0%$467.48m
REGNRegeneron Pharmaceuticals, Inc. -0.24%480.002.7%$430.61m
VRTXVertex Pharmaceuticals, Inc. 0.00%217.131.9%$373.76m
ALXNAlexion Pharmaceuticals, Inc. 0.00%155.292.0%$316.00m
BIIBBiogen, Inc. 0.00%265.791.7%$265.53m
BNTXBioNTech SE 1.53%134.630.0%$239.95m
EXASEXACT Sciences Corp. 0.00%127.1418.4%$192.79m
CRSPCRISPR Therapeutics AG 1.50%124.960.6%$179.57m
NBIXNeurocrine Biosciences, Inc. 0.00%95.054.9%$177.79m
TWSTTwist Bioscience Corp. -0.32%141.570.0%$150.49m

Company Profile

BioNTech SE is a next-generation immunotherapy company, which treats cancer and other serious diseases. It exploits an array of discovery and therapeutic drug platforms for the development of novel biopharmaceuticals. The company's portfolio of infectious disease and oncology product candidates include FixVac, iNeST (Individualized Neoantigen Specific Immunotherapy), Intratumoral Immunotherapies, RiboMabs, RiboCytokines, CAR T Cell Platform, T Cell Receptor(TCR), Checkpoint Immunomodulator, Targeted Cancer Antibodies, and Small Molecule Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.